PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Intra-arterial (IA) alteplase was associated with superior 90-day functional outcomes than standard therapy alone in Chinese patients with large-vessel occlusion (LVO) stroke who had achieved ...
Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback